AgingResearch.NewsJoin free

Mentara Therapeutics

CompanyUnited States

Mentara Therapeutics develops one asset, in phase 2 (MTA-304 in levodopa-induced dyskinesia in Parkinson's disease). Mostly small molecule acting on PDE10A; based in the United States.

1
Asset
Furthest stage
Phase 2
0
Trials
1
Signal

Pipeline

1

  • MTA-304

    Inhibition of phosphodiesterase 10A (PDE10A).

    Phase 2, Small molecule, PDE10A, levodopa-induced dyskinesia in Parkinson's disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Signals1

Intelligence